preclinical_heavy
Preclinical evidence exceeds central human evidence. Interpret translational relevance cautiously.
supportedtophigh inflation risk
Parabacteroides distasonis
inflammatory bowel disease
Parabacteroides distasonis has meaningful literature visibility in inflammatory bowel disease, but the current evidence mix suggests a substantial risk of overclaiming.
Parabacteroides distasonis shows a moderate evidence base in inflammatory bowel disease, with multiple central papers and additional supporting literature.
parabacteroides_distasonis
Credibility score
48
Human translation
2/5
Reproducibility
3/5
Novelty
3/5
Actionability
3/5
Credibility 48Human translation 2/5Reproducibility 3/5Novelty 3/5Actionability 3/5
Why this scores the way it does
- moderate central evidence base
- substantial preclinical support
Main caveats
- preclinical evidence outweighs human evidence
Internal review flags
1 flagsPrimary central evidence
13 papersCharacterization of adherent bacteroidales from intestinal biopsies of children and young adults with inflammatory bowel disease.
2013PloS one
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Compositional changes to the ileal microbiome precede the onset of spontaneous ileitis in SHIP deficient mice.
2019Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Isolation of Anti-Inflammatory and Epithelium Reinforcing Bacteroides and Parabacteroides Spp. from A Healthy Fecal Donor.
2020Nutrients
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Utilizing a reductionist model to study host-microbe interactions in intestinal inflammation.
2021Microbiome
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Analysis of gut microbiome profiles in common marmosets (Callithrix jacchus) in health and intestinal disease.
2022Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Tissue-dependent transcriptional and bacterial associations in primary sclerosing cholangitis-associated inflammatory bowel disease.
2021Wellcome open research
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Integrating the serum proteomic and fecal metaproteomic to analyze the impacts of overweight/obesity on IBD: a pilot investigation.
2023Clinical proteomics
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Dynamics of the Gut Mycobiome in Patients With Ulcerative Colitis.
2024Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Early-life gut microbiota in food allergic children and its impact on the development of allergic disease.
2023Italian journal of pediatrics
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Alterations of the Gut Microbiome and TMAO Levels in Patients with Ulcerative Colitis.
2024Journal of clinical medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Culture-based characterization of gut microbiota in inflammatory bowel disease.
2025Frontiers in microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut Microbial Signatures Associated With Clinical Remission in Inflammatory Bowel Disease Treated With Biologics: A Comprehensive Multi-Cohort Analysis.
2025United European gastroenterology journal
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Predicting Risk of Post-Treatment Relapse in Patients with Inflammatory Bowel Disease Based on Intestinal Microbiota.
2025Journal of inflammation research
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Supporting primary evidence
1 papersComplete Genome Sequence of a Parabacteroides distasonis Strain (CavFT hAR46) Isolated from a Gut Wall-Cavitating Microlesion in a Patient with Severe Crohn's Disease.
2019Microbiology resource announcements
Human primary paper with plausible association relevance to the disease context.
Preclinical supporting evidence
23 papersOral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition.
2011Clinical and experimental immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Pglyrp-Regulated Gut Microflora Prevotella falsenii, Parabacteroides distasonis and Bacteroides eggerthii Enhance and Alistipes finegoldii Attenuates Colitis in Mice.
2016PloS one
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut microbiota modulation and anti-inflammatory properties of anthocyanins from the fruits of Lycium ruthenicum Murray in dextran sodium sulfate-induced colitis in mice.
2019Free radical biology & medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
In Vitro Characterization of Gut Microbiota-Derived Commensal Strains: Selection of Parabacteroides distasonis Strains Alleviating TNBS-Induced Colitis in Mice.
2020Cells
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Parabacteroides distasonis induces depressive-like behavior in a mouse model of Crohn's disease.
2021Brain, behavior, and immunity
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Linarin ameliorates dextran sulfate sodium-induced colitis in C57BL/6J mice via the improvement of intestinal barrier, suppression of inflammatory responses and modulation of gut microbiota.
2022Food & function
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Parabacteroides distasonis Properties Linked to the Selection of New Biotherapeutics.
2022Nutrients
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Polysaccharide from Edible Alga Enteromorpha clathrata Improves Ulcerative Colitis in Association with Increased Abundance of Parabacteroides spp. in the Gut Microbiota of Dextran Sulfate Sodium-Fed Mice.
2022Marine drugs
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Parabacteroides distasonis ameliorates hepatic fibrosis potentially via modulating intestinal bile acid metabolism and hepatocyte pyroptosis in male mice.
2023Nature communications
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Regulation of gut microbiota and alleviation of DSS-induced colitis by vitexin.
2023European journal of nutrition
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Akkermansia muciniphila and Parabacteroides distasonis synergistically protect from colitis by promoting ILC3 in the gut.
2024mBio
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Integrative analysis with microbial modelling and machine learning uncovers potential alleviators for ulcerative colitis.
2024Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut Microbiota Profile Changes in Patients with Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease: A Metagenomic Study.
2024International journal of molecular sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Vinegar-processed Schisandra Chinensis enhanced therapeutic effects on colitis-induced depression through tryptophan metabolism.
2024Phytomedicine : international journal of phytotherapy and phytopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Daikenchuto, a Japanese herbal medicine, ameliorates experimental colitis in a murine model by inducing secretory leukocyte protease inhibitor and modulating the gut microbiota.
2024Frontiers in immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Microbiota-derived IPA alleviates intestinal mucosal inflammation through upregulating Th1/Th17 cell apoptosis in inflammatory bowel disease.
2025Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Oral Sheep Milk-Derived Exosome Therapeutics for Cadmium-Induced Inflammatory Bowel Disease.
2025International journal of molecular sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
CD8+ T Cell-Derived Perforin Exacerbates Dysbiosis and Inflammatory Bowel Disease via β-Hydroxybutyrate Suppression in Mouse Colonic Epithelium.
2025Journal of inflammation research
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Microbiota composition-based donor selection affects FMT efficacy in a murine colitis model.
2025Frontiers in immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bifidobacterium breve B2798 and Its Heat-Killed Cells Alleviate Inflammation in Rats with DSS Model by Modulating Gut Microbiota.
2025Probiotics and antimicrobial proteins
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Novel plant-derived compounds modulate gut microbiome dysbiosis in colitis mice: A potential therapeutic avenue for inflammatory bowel disease.
2026Microbiological research
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Annexin A1 levels affect microbiota in health and DSS-induced colitis/inflammatory bowel disease development.
2025Frontiers in immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Parabacteroides goldsteinii mitigates parkinsonism in LRRK2 mutant mice by reducing neuroinflammation through Gut-Brain axis.
2025Journal of advanced research
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
6 papersAlterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis.
2021International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Parabacteroides distasonis: intriguing aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and probiotic roles in human health.
2021Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Gut bacteriome in inflammatory bowel disease: An update on recent advances.
2024Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Therapeutic potential of Parabacteroides distasonis in gastrointestinal and hepatic disease.
2024MedComm
Relevant review or meta-analysis for the signal-disease area.
Therapeutic potential of the gut commensal bacterium Parabacteroides goldsteinii in human health and disease treatment.
2025Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Gut microbiome remodeling induced by microplastic exposure in humans.
2026Gut microbes
Relevant review or meta-analysis for the signal-disease area.